Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.…
PRISM MarketView Highlights Seven Small-Cap Lung Cancer Developers for Lung Cancer Awareness Month
Candel Therapeutics (NASDAQ: CADL) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 55 employees.
The shares were at 5.040 USD on 20 November 2026, roughly unchanged over 52 weeks. Its 52-week range is 4.350 USD to 13.85 USD: the price is 63.6% below the high and 15.9% above the low.
Its market capitalisation is 395.37M USD.
Candel Therapeutics reports return on equity of -73.5% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 153.35M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 9 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 17.67 USD is 250.5% above the current price. The next earnings report is expected on 11 March 2027.